Which anticholinergic is best for people with overactive bladders?

A network meta-analysis

G. Peter Herbison, Joanne E. McKenzie

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Aim: To carry out a network meta-analysis of randomised controlled trials (RCTs) of anticholinergic drug treatment for people with overactive bladders. Methods: Comprehensive searches for relevant RCTs were carried out starting with RCTs included in previous systematic reviews with the last search in February 2017. Searches included terms for the anticholinergic drugs tolterodine, oxybutynin, trospium, propiverine, solifenacin, darifenacin, imidafenacin, and fesoterodine. Data was extracted from the systematic reviews or reports of studies for cure or improvement, voids per 24 hr, leakage episodes per 24 hr and dry mouth. Data was analysed using frequentist network meta-analysis. Results: 128 studies were found. There was no clearly best treatment for cure or improvement. The differences between treatments for voids and leakages were small and unlikely to be of clinical importance. Transdermally delivered oxybutynin was clearly the best treatment for dry mouth but was still worse than placebo. Conclusions: All the anticholinergic drugs were better than placebo but apart from dry mouth were similar in effect. Transdermal oxybutynin caused less dry mouth than the other treatments, so may be worth considering as the first treatment.

Original languageEnglish
Pages (from-to)525-534
Number of pages10
JournalNeurourology and Urodynamics
Volume38
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • anticholinergics
  • antimuscarinics
  • network meta-analysis
  • overactive bladder

Cite this

@article{e23d5e4a99aa4fb5bc1e17cf320c6cda,
title = "Which anticholinergic is best for people with overactive bladders?: A network meta-analysis",
abstract = "Aim: To carry out a network meta-analysis of randomised controlled trials (RCTs) of anticholinergic drug treatment for people with overactive bladders. Methods: Comprehensive searches for relevant RCTs were carried out starting with RCTs included in previous systematic reviews with the last search in February 2017. Searches included terms for the anticholinergic drugs tolterodine, oxybutynin, trospium, propiverine, solifenacin, darifenacin, imidafenacin, and fesoterodine. Data was extracted from the systematic reviews or reports of studies for cure or improvement, voids per 24 hr, leakage episodes per 24 hr and dry mouth. Data was analysed using frequentist network meta-analysis. Results: 128 studies were found. There was no clearly best treatment for cure or improvement. The differences between treatments for voids and leakages were small and unlikely to be of clinical importance. Transdermally delivered oxybutynin was clearly the best treatment for dry mouth but was still worse than placebo. Conclusions: All the anticholinergic drugs were better than placebo but apart from dry mouth were similar in effect. Transdermal oxybutynin caused less dry mouth than the other treatments, so may be worth considering as the first treatment.",
keywords = "anticholinergics, antimuscarinics, network meta-analysis, overactive bladder",
author = "Herbison, {G. Peter} and McKenzie, {Joanne E.}",
year = "2019",
month = "2",
doi = "10.1002/nau.23893",
language = "English",
volume = "38",
pages = "525--534",
journal = "Neurourology and Urodynamics",
issn = "0733-2467",
publisher = "Wiley-Blackwell",
number = "2",

}

Which anticholinergic is best for people with overactive bladders? A network meta-analysis. / Herbison, G. Peter; McKenzie, Joanne E.

In: Neurourology and Urodynamics, Vol. 38, No. 2, 02.2019, p. 525-534.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Which anticholinergic is best for people with overactive bladders?

T2 - A network meta-analysis

AU - Herbison, G. Peter

AU - McKenzie, Joanne E.

PY - 2019/2

Y1 - 2019/2

N2 - Aim: To carry out a network meta-analysis of randomised controlled trials (RCTs) of anticholinergic drug treatment for people with overactive bladders. Methods: Comprehensive searches for relevant RCTs were carried out starting with RCTs included in previous systematic reviews with the last search in February 2017. Searches included terms for the anticholinergic drugs tolterodine, oxybutynin, trospium, propiverine, solifenacin, darifenacin, imidafenacin, and fesoterodine. Data was extracted from the systematic reviews or reports of studies for cure or improvement, voids per 24 hr, leakage episodes per 24 hr and dry mouth. Data was analysed using frequentist network meta-analysis. Results: 128 studies were found. There was no clearly best treatment for cure or improvement. The differences between treatments for voids and leakages were small and unlikely to be of clinical importance. Transdermally delivered oxybutynin was clearly the best treatment for dry mouth but was still worse than placebo. Conclusions: All the anticholinergic drugs were better than placebo but apart from dry mouth were similar in effect. Transdermal oxybutynin caused less dry mouth than the other treatments, so may be worth considering as the first treatment.

AB - Aim: To carry out a network meta-analysis of randomised controlled trials (RCTs) of anticholinergic drug treatment for people with overactive bladders. Methods: Comprehensive searches for relevant RCTs were carried out starting with RCTs included in previous systematic reviews with the last search in February 2017. Searches included terms for the anticholinergic drugs tolterodine, oxybutynin, trospium, propiverine, solifenacin, darifenacin, imidafenacin, and fesoterodine. Data was extracted from the systematic reviews or reports of studies for cure or improvement, voids per 24 hr, leakage episodes per 24 hr and dry mouth. Data was analysed using frequentist network meta-analysis. Results: 128 studies were found. There was no clearly best treatment for cure or improvement. The differences between treatments for voids and leakages were small and unlikely to be of clinical importance. Transdermally delivered oxybutynin was clearly the best treatment for dry mouth but was still worse than placebo. Conclusions: All the anticholinergic drugs were better than placebo but apart from dry mouth were similar in effect. Transdermal oxybutynin caused less dry mouth than the other treatments, so may be worth considering as the first treatment.

KW - anticholinergics

KW - antimuscarinics

KW - network meta-analysis

KW - overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=85058948038&partnerID=8YFLogxK

U2 - 10.1002/nau.23893

DO - 10.1002/nau.23893

M3 - Review Article

VL - 38

SP - 525

EP - 534

JO - Neurourology and Urodynamics

JF - Neurourology and Urodynamics

SN - 0733-2467

IS - 2

ER -